UBS Group
RGNX icon

UBS Group’s Regenxbio RGNX Stock Holding History

UBS Group’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,400
Closed -$96.9K – 9904
2023
Q4 		$96.9K Sell
5,400
-43,900
-89% -$773K ﹤0.01% 6188
2023
Q3 		$811K Hold
49,300
– – ﹤0.01% 4271
2023
Q2 		$986K Buy
+49,300
New +$950K ﹤0.01% 4256
2021
Q4 		– Sell
-10,000
Closed -$419K – 10627
2021
Q3 		$419K Buy
+10,000
New +$360K ﹤0.01% 4846

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

UBS Group's RGNX Position: Q2 2026 in Review

UBS Group reduced its Regenxbio (RGNX) stake by 2.9% in Q2 2026, selling an estimated $62.4K and leaving 249,947 shares worth $2.99M. The position accounts for ﹤0.01% of the portfolio, ranked #4696.

UBS Group first reported a position in RGNX in Q3 2015 and has held it in 41 quarters since. The position peaked at $26.8M in Q4 2019. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • UBS Group held 249,947 shares of Regenxbio worth $2.99M as of Q2 2026.
  • UBS Group sold 7,516 Regenxbio shares in Q2 2026, an estimated $62.4K.
  • Regenxbio made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4696 holding.
  • UBS Group first reported a position in Regenxbio in Q3 2015 and has held it in 41 quarters since.
  • UBS Group's Regenxbio position peaked at $26.8M in Q4 2019.
  • 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.